Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Contributed by: PR Newswire

Tags

H-Lundbeck-A/S

More Like This

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

PR Newswire associated0

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations